A. Vorog

发表

Human immunodeficiency virus infection and chronic myeloid leukemia.

F. Fazel, A. Karstaedt, Moosa Patel, 2012, Leukemia research.

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

U. Mellqvist, M. Dimopoulos, Shaji K. Kumar, 2022, Blood cancer journal.

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

G. Morgan, M. Dimopoulos, A. Palumbo, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

U. Mellqvist, M. Dimopoulos, Shaji K. Kumar, 2021 .

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

H. Dombret, M. Vignetti, E. Jabbour, 2021, HemaSphere.

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

K. Suryanarayan, M. Dimopoulos, S. Lonial, 2023, Blood Cancer Journal.

MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials.

K. Suryanarayan, M. Dimopoulos, B. Paiva, 2022, Blood.

CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial.

G. Rosti, J. Cortes, M. Deininger, 2022, Clinical lymphoma, myeloma & leukemia.

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

J. Dipersio, H. Kantarjian, G. Rosti, 2021, Blood.

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.

M. Dimopoulos, D. Cherepanov, R. Benjamin, 2023, Clinical lymphoma, myeloma & leukemia.

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

K. Suryanarayan, G. Morgan, M. Dimopoulos, 2021, Blood.

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

G. Rosti, J. Cortes, M. Deininger, 2022, Blood.

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

H. Kantarjian, E. Jabbour, I. Aldoss, 2023, Journal of Clinical Oncology.

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

H. Kantarjian, I. Aldoss, C. Gambacorti-Passerini, 2024, JAMA.

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

H. Kantarjian, G. Rosti, C. Chuah, 2024, Leukemia.

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

G. Rosti, M. Deininger, C. Chuah, 2022, Blood.